You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ):擬分拆川寧生物至深交所創業板上市
格隆匯 06-17 20:29

格隆匯6月17日丨科倫藥業(002422.SZ)公佈,公司擬將其控股子公司川寧生物分拆至深交所創業板上市。本次分拆完成後,科倫藥業股權結構不會發生變化,且仍將保持對川寧生物的控制權。

通過此次分拆,川寧生物作為公司下屬生物發酵產業抗生素中間體業務的主要平台將實現獨立上市,並通過創業板融資增強資金實力,提升川寧生物的盈利能力和綜合競爭力。

次發行均為新股,不涉及股東公開發售股份。此次發行不超2.228億股(含,且不低於本次發行後川寧生物總股本的10%)。最終發行數量由川寧生物股東大會授權川寧生物董事會根據有關監管機構的要求、證券市場的實際情況、發行前股本數量、募集資金項目資金需求量等,與主承銷商協商確定。如川寧生物在本次發行上市前發生送股、資本公積轉增股本等除權事項,則擬發行的股份數量將作相應調整

川寧生物負責公司抗生素中間體業務的開展,主要從事生物發酵技術的研發和產業化,主要產品為硫氰酸紅黴素、青黴素類抗生素中間體(包括6-APA、青黴素G鉀鹽)、頭孢類抗生素中間體(包括7-ACAD-7ACA7-ADCA)以及熊去氧膽酸等。川寧生物與公司其他業務板塊保持較高的獨立性,公司此次分拆不會對其他業務板塊持續經營構成實質性影響,此次分拆後公司主營業務領域不會發生變化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account